loading...| Preferred Name |
octreotide acetate |
|
| Synonyms |
Sandostatina |
|
| Definitions |
The acetate salt of a synthetic long-acting cyclic octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. Octreotide is a more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Similar to somatostatin, this agent also suppresses the luteinizing hormone response to gonadotropin-releasing hormone, decreases splanchnic blood flow, and inhibits the release of serotonin, gastrin, vasoactive intestinal peptide (VIP), secretin, motilin, pancreatic polypeptide, and thyroid stimulating hormone. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C53447" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C53447" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000038866 |
|
| altLabel |
Sandostatina D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide acetate Longastatin Sandostatin SMS 201-995 Sandostatin Lar Depot Samilstin Sandostatine Longastatina |
|
| CAS Registry |
79517-01-4 |
|
| Component of |
http://purl.bioontology.org/ontology/PDQ/CDR0000042430 http://purl.bioontology.org/ontology/PDQ/CDR0000438715 http://purl.bioontology.org/ontology/PDQ/CDR0000039125 http://purl.bioontology.org/ontology/PDQ/CDR0000363632 http://purl.bioontology.org/ontology/PDQ/CDR0000038072 http://purl.bioontology.org/ontology/PDQ/CDR0000038164 http://purl.bioontology.org/ontology/PDQ/CDR0000043019 |
|
| cui |
C1518539 C1170602 C1518540 C0728977 C1521974 C0678117 C0724649 C1709307 |
|
| Date last modified |
2006-07-19 |
|
| definition |
The acetate salt of a synthetic long-acting cyclic octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. Octreotide is a more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Similar to somatostatin, this agent also suppresses the luteinizing hormone response to gonadotropin-releasing hormone, decreases splanchnic blood flow, and inhibits the release of serotonin, gastrin, vasoactive intestinal peptide (VIP), secretin, motilin, pancreatic polypeptide, and thyroid stimulating hormone. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C53447" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C53447" NCI Thesaurus) |
|
| Legacy PDQ ID |
1356 |
|
| LT |
TRD |
|
| NCI ID |
C53447 |
|
| notation |
CDR0000038866 |
|
| NSC Code |
671663 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
octreotide acetate |
|
| tui |
T125 T116 T121 |